Ask Me Anything on Asian equities
Feel free to ask anything that's on your mind
Today I’ll be hosting another Ask Me Anything thread for both free + paid subscribers.
Ask about any questions you might have, for example:
Who are the beneficiaries of Singapore’s border re-opening?
What is going on with Chinese ADRs and their recent buyback announcements?
How will China’s crackdown on junket operators affect regional casinos?
What will happen to Asian oil & gas stocks in case of a ceasefire in Ukraine?
What does Sri Lanka’s crisis portend for the rest of the region?
Also - a friendly reminder that the yearly price for a subscription will go up tomorrow morning from $299 to $349. You’ll get 20+ deep-dive reports on Asian stocks per year and full disclosure of my personal portfolio.
So if you’ve been considering subscribing - now is a good time to do so. You’ll lock in the lower $299 price forever as long as you remain a subscriber.
Disclaimer: Asian Century Stocks uses information sources believed to be reliable, but their accuracy cannot be guaranteed. Asian Century Stocks is not regulated under the Financial Advisers Act and should not be regarded as a financial adviser. The information contained in this publication is not intended to constitute individual investment advice and is not designed to meet your personal financial situation. It is for entertainment purposes only. You are advised to discuss your investment options with your financial adviser and to understand whether any investment is suitable for your specific needs. The opinions expressed in the below discussion are those of the publisher and are subject to change without notice. I may, from time to time, have positions in the securities covered in the articles on this website.
Thanks for doing this!
1. Do you happen to have a take on China biopharma and in seeking opportunities here? I came a startling statistic about the market value of publicly listed biopharma innovation players from China going from $3 billion in 2016 to more than $380 billion in July 2021. https://www.mckinsey.com/industries/life-sciences/our-insights/the-dawn-of-china-biopharma-innovation
2. Any views on Alibaba especially with respect to regulatory news?
Will the AMA be held on reddit?